Zymeworks Valuation
Is ZYME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ZYME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZYME?
Other financial metrics that can be useful for relative valuation.
| What is ZYME's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$937.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9x |
| Enterprise Value/EBITDA | -4.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ZYME's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.2x | ||
AUPH Aurinia Pharmaceuticals | 4.9x | 17.5% | US$998.1m |
SLN Silence Therapeutics | 39.3x | 28.4% | US$898.5m |
NRIX Nurix Therapeutics | 24.4x | 26.5% | US$1.4b |
BCRX BioCryst Pharmaceuticals | 4x | 15.6% | US$1.5b |
ZYME Zymeworks | 15x | 8.2% | US$937.8m |
Price-To-Sales vs Peers: ZYME is good value based on its Price-To-Sales Ratio (15x) compared to the peer average (18.2x).
Price to Earnings Ratio vs Industry
How does ZYME's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ZYME is expensive based on its Price-To-Sales Ratio (15x) compared to the US Biotechs industry average (11.5x).
Price to Sales Ratio vs Fair Ratio
What is ZYME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 15x |
| Fair PS Ratio | 1.1x |
Price-To-Sales vs Fair Ratio: ZYME is expensive based on its Price-To-Sales Ratio (15x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$13.20 | US$13.90 +5.3% | 23.8% | US$21.00 | US$10.00 | n/a | 8 |
| Oct ’25 | US$12.35 | US$13.90 +12.6% | 23.8% | US$21.00 | US$10.00 | n/a | 8 |
| Sep ’25 | US$11.73 | US$14.19 +21.0% | 25.7% | US$21.00 | US$10.00 | n/a | 9 |
| Aug ’25 | US$10.11 | US$14.08 +39.2% | 24.5% | US$20.00 | US$10.00 | n/a | 9 |
| Jul ’25 | US$8.61 | US$13.94 +61.9% | 26.0% | US$20.00 | US$10.00 | n/a | 8 |
| Jun ’25 | US$8.48 | US$13.72 +61.8% | 25.3% | US$20.00 | US$10.00 | n/a | 9 |
| May ’25 | US$8.76 | US$14.17 +61.7% | 26.1% | US$21.00 | US$10.00 | n/a | 9 |
| Apr ’25 | US$9.88 | US$14.17 +43.4% | 26.1% | US$21.00 | US$10.00 | n/a | 9 |
| Mar ’25 | US$12.51 | US$13.28 +6.1% | 28.2% | US$19.00 | US$8.00 | n/a | 9 |
| Feb ’25 | US$10.98 | US$13.37 +21.8% | 27.8% | US$19.00 | US$8.00 | n/a | 10 |
| Jan ’25 | US$10.39 | US$13.37 +28.7% | 27.8% | US$19.00 | US$8.00 | n/a | 10 |
| Dec ’24 | US$9.15 | US$13.52 +47.7% | 26.4% | US$19.00 | US$8.00 | n/a | 11 |
| Nov ’24 | US$7.02 | US$13.52 +92.6% | 27.5% | US$19.00 | US$8.00 | n/a | 11 |
| Oct ’24 | US$6.34 | US$13.52 +113.2% | 27.5% | US$19.00 | US$8.00 | US$12.35 | 11 |
| Sep ’24 | US$7.49 | US$13.52 +80.5% | 27.5% | US$19.00 | US$8.00 | US$11.73 | 11 |
| Aug ’24 | US$7.45 | US$13.61 +82.7% | 28.0% | US$19.00 | US$8.00 | US$10.11 | 11 |
| Jul ’24 | US$8.64 | US$13.61 +57.5% | 28.0% | US$19.00 | US$8.00 | US$8.61 | 11 |
| Jun ’24 | US$8.49 | US$13.61 +60.3% | 28.0% | US$19.00 | US$8.00 | US$8.48 | 11 |
| May ’24 | US$8.43 | US$13.45 +59.6% | 26.8% | US$18.50 | US$8.00 | US$8.76 | 11 |
| Apr ’24 | US$9.04 | US$13.45 +48.8% | 26.8% | US$18.50 | US$8.00 | US$9.88 | 11 |
| Mar ’24 | US$8.01 | US$13.73 +71.4% | 30.5% | US$21.00 | US$8.00 | US$12.51 | 11 |
| Feb ’24 | US$9.27 | US$13.45 +45.1% | 32.6% | US$21.00 | US$8.00 | US$10.98 | 11 |
| Jan ’24 | US$7.86 | US$12.83 +63.3% | 34.0% | US$21.00 | US$8.00 | US$10.39 | 12 |
| Dec ’23 | US$7.73 | US$12.31 +59.2% | 39.1% | US$21.00 | US$7.00 | US$9.15 | 12 |
| Nov ’23 | US$7.45 | US$13.10 +75.8% | 44.7% | US$24.00 | US$7.00 | US$7.02 | 12 |
| Oct ’23 | US$6.15 | US$20.98 +241.1% | 52.7% | US$45.00 | US$7.00 | US$6.34 | 12 |
Analyst Forecast: Target price is less than 20% higher than the current share price.